Role of JAK2-STAT3 signaling pathway in tumorigenesis and development

Abstract

Abstract:

JAK2-STAT3 signaling pathway, as the main chain of intracellular signal transmission, plays an important role in cell proliferation, apoptosis, invasion, migration and immune response. Triggered by cytokines and interferon, this pathway can quickly transduce extracellular signals into the nucleus, and it has abnormal expression in various tumors, such as squamous cell carcinoma of the head and neck, lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer and myeloproliferative neoplasms. Further understanding of the carcinogenic mechanism of JAK2-STAT3 signaling pathway can provide new ideas for clinical treatment of tumors and prognosis.

Key words:Neoplasms,JAK2-STAT3 signaling pathway

Luo Pan, Zeng Yan, Wu Weili. Role of JAK2-STAT3 signaling pathway in tumorigenesis and development[J]. Journal of International Oncology, 2021, 48(12): 739-742.

References27

[1]	Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins[J]. Science, 1994,264(5164):1415-1421. DOI: 10.1126/science.8197455.
[2]	Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact[J]. Nat Rev Mol Cell Biol, 2002,3(9):651-662. DOI: 10.1038/nrm909.
[3]	Liu JF, Deng WW, Chen L, et al. Inhibition of JAK2-STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer[J]. Mol Carcinog, 2018,57(3):429-439. DOI: 10.1002/mc.22767.
[4]	Peng HY, Cheng YC, Hsu YM, et al. MPT0B098, a microtubule inhibitor, suppresses JAK2-STAT3 signaling pathway through modulation of SOCS3 stability in oral squamous cell carcinoma[J]. PLoS One, 2016,11(7):e0158440. DOI: 10.1371/journal.Pone.0158440.
[5]	Yadav A, Kumar B, Datta J, et al. IL-6 promotes head and necktumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway[J]. Mol Cancer Res, 2011,9(12):1658-1667. DOI: 10.1158/1541-7786.MCR-11-0271.
[6]	He HL, Lee YE, Liang PI, et al. Overexpression of JAK2: a predictor of unfavorable prognosis for nasopharyngeal carcinoma[J]. Future Oncol, 2016,12(16):1887-1896. DOI: 10.2217/fon-2016-0025.
[7]	Lin CH, Chiang MC, Chen YJ. STAT3 mediates resistance toanoikis and promotes invasiveness of nasopharyn geal cancer cells[J]. Int J Mol Med, 2017,40(5):1549-1556. DOI: 10.3892/ijmm.2017.3151.
[8]	Xu Y, Jin J, Xu J, et al. JAK2 variations and functions in lung adenocarcinoma[J]. Tumour Biol, 2017,39(6):1010428317711140. DOI: 10.1177/1010428317711140.
[9]	Wang M, Lin T, Wang Y, et al. CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2-STAT3 signaling in human non-small-cell lung cancer cells[J]. Onco Targets Ther, 2017,10:3215-3224. DOI: 10.2147/OTT.S133055.
[10]	Pastuszak-Lewandoska D, Domańska-Senderowska D, Kordiak J, et al. Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non-small-cell lung cancer[J]. Pol Arch Intern Med, 2017,127(11):758-764. DOI: 10.20452/pamw.4115.
[11]	Dong Y, Xu T, Zhong S, et al. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p[J]. Life Sci, 2019,239:116984. DOI: 10.1016/j.lfs.2019.116984.
[12]	Fang J, Chu L, Li C, et al. JAK2 inhibitor blocks the inflammation and growth of esophageal squamous cell carcinoma in vitro through the JAK-STAT3 pathway[J]. Oncol Rep, 2015,33(1):494-502. DOI: 10.389 2/or.2014.3609.
[13]	Liu JR, Wu WJ, Liu SX, et al. Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2-STAT3 pathway[J]. Pathol Res Pract, 2015,211(6):426-434. DOI: 10.1016/j.prp.2015.01.007.
[14]	Liu J, Mao Y, Zhang D, et al. Retraction notice to "MiR-143 inhibits tumor cell proliferation and invasion by targeting STAT3 in esophageal squamous cell carcinoma"[J]. Cancer Lett, 2018,422:133. DOI: 10.1016/j.canlet.2018.03.021.
[15]	Yan XL, Luo QY, Zhou SN, et al. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2-STAT3 signaling pathways in gastric cancer[J]. Clin Res Hepatol Gastroenterol, 2020,30:101574. DOI: 10.1016/j.clinre.2020.10.015.
[16]	陶有茂 . MicroRNA-216a通过抑制JAK2-STAT3信号通路抑制胃癌细胞侵袭转移及上皮间质转化[D]. 吉林大学, 2019.
[17]	Xu XF, Gao F, Wang JJ, et al. BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK-STAT3 signaling pathway[J]. Cancer Cell Int, 2019,19:133. DOI: 10.1186/s12935-019-0847-5.
[18]	Hin Tang JJ, Hao Thng DK, Lim JJ, et al. JAK-STAT signaling in hepatocellular carcinoma[J]. Hepat Oncol, 2020, 7(1): HEP18. DOI: 10.2217/hep-2020-0001.
[19]	Kondo R, Ishino K, Wada R, et al. Downregulation of protein disulfide-isomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling inhepatocellular carcinoma[J]. Int J Oncol, 2019,54(4):1409-1421. DOI: 10.3892/ijo.2019.4710.
[20]	Choe MH, Min JW, Jeon HB, et al. ERp57 modulates STAT3 activity in radioresistant laryngeal cancer cells and serves as a prognostic marker for laryngeal cancer[J]. Oncotarget, 2015,6(5):2654-2666. DOI: 10.18632/oncotarget.3042.
[21]	Wan S, Zhao E, Kryczek I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J]. Gastroenterology, 2014,147(6):1393-1404. DOI: 10.1053/j.gastro.2014.08.039.
[22]	Chang R, Song L, Xu Y, et al. Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2-STAT3 axis[J]. Nat Commun, 2018,9(1):3486. DOI: 10.1038/s41467-018-05852-8.
[23]	Cheng M, Liu P, Xu LX. Iron promotes breast cancer cell migration via IL-6/JAK2/STAT3 signaling pathways in a paracrine or autocrine IL-6-rich inflammatory environment[J]. J Inorg Biochem, 2020,210:111159. DOI: 10.1016/j.jinorgbio.2020.11115.
[24]	Wang S, Liang K, Hu Q, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis[J]. J Clin Invest, 2017,127(12):4498-4515. DOI: 10.1172/JCI91553.
[25]	Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases[J]. Pharmacol Res, 2016,111:784-803. DOI: 10.1016/j.phrs.2016.07.038.
[26]	Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib[J]. Cancer Chemother Pharmacol, 2016,77(6):1125-1142. DOI: 10.1007/s00280-016-3012-z.
[27]	Shastri A, Choudhary G, Teixeira M, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells[J]. J Clin Invest, 2018,128(12):5479-5488. DOI: 10.1172/JCI120156.